The largest community of pharma leaders

Cyclo Therapeutics Reports Publication of International Patent Application for Treatment of Alzheimer’s Disease

ALACHUA, Fla.–()–Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease, today announced that the international patent application titled “Methods for Treating Alzheimer’s Disease” was published as International Publication Number: WO 2020/092107 Al.

The patent application describes treating Alzheimer’s Disease with the Company’s Trappsol® Cyclo™ hydroxypropyl beta cyclodextrin product. Inventors on the patent are Sharon H. Hrynkow, Ph.D., Jeffrey L. Tate, Ph.D. and N. Scott Fine, all of whom are Company officers.

“Publication of this international patent application marks further progress for the Company as we develop Trappsol® Cyclo™ for additional indications,” said Cyclo Therapeutics’ Chairman and CEO, N. Scott Fine. “Alzheimer’s Disease is a growing health problem and innovative methods for addressing it, like ours, are needed.”

“Alzheimer’s Disease takes an enormous toll on those who suffer from it, along with family members, and societies,” said Cyclo Therapeutics’ Chief Scientific Officer and Senior V.P. for Medical Affairs Dr. Sharon Hrynkow. “With no approved disease modifying treatments, new approaches to its treatment like the one described in this patent application are urgently needed.”

About Cyclo Therapeutics:

Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C and Alzheimer’s Disease. The company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is the subject of three ongoing formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease, ( NCT02939547, NCT02912793 and NCT03893071). The company is planning an early phase clinical trial using Trappsol® Cyclo™ intravenously in Alzheimer’s Disease based on encouraging data from an Expanded Access program for late-onset Alzheimer’s Disease (NCT03624842). Additional indications for the active ingredient in Trappsol® Cyclo™ are in development. For additional information, visit the company’s website:

Safe Harbor Statement:

This press release contains “forward-looking statements” about the company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence the company’s future performance include the company’s ability to obtain additional capital to expand operations as planned, success in achieving regulatory approval for clinical protocols, enrollment of adequate numbers of patients in clinical trials, unforeseen difficulties in showing efficacy of the company’s biopharmaceutical products, success in attracting additional customers and profitable contracts, and regulatory risks associated with producing pharmaceutical grade and food products. These and other risk factors are described from time to time in the company’s filings with the Securities and Exchange Commission, including, but not limited to, the company’s reports on Forms 10-K and 10-Q. Unless required by law, the company assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.


Recent Articles